Equillium Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to ...

inhibits the anti-tumor activity of natural killer (NK) cells through its receptor. They also proposed a new immunotherapy strategy based on receptor antagonism. Their study was published in ...

Compass Therapeutics (CMPX) announced its poster presentation entitled “Pharmacodynamic and Response Biomarkers in the Monotherapy Arm of ...

MDNA11 showed significant increases in markers of stemness, central and effector memory and enhanced effector function in circulating CD8+ T and NK cells. Analysis of paired biopsies showed increased ...

and NK (natural killer) cells. Measurements showed that VNPs had lower zonulin levels, a marker indicating gut mucosal disruption, implying better gut integrity than progressors. Metabolomic ...

These mice also exhibit a disrupted skin barrier, dysregulated microbiome, and upregulated JAK1/2 and STAT1 signaling caused by T cell- and NK cell-derived interferon ... Importantly, the loss of HFSC ...